72
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension

, , , , &
Pages 1459-1463 | Published online: 08 Dec 2010

Figures & data

Table 1 Patient demographics of the safety population

Figure 1 Decrease in diurnal IOP from baseline produced by travoprost and tafluprost. (intent-to-treat population, N = 48).

Note: *Travoprost showed a significantly larger decrease in IOP from baseline than tafluprost (P < 0.05).
Abbreviation: IOP, intraocular pressure.
Figure 1 Decrease in diurnal IOP from baseline produced by travoprost and tafluprost. (intent-to-treat population, N = 48).

Table 2 Mean intraocular pressure at baseline and after six weeks of therapy with travoprost and tafluprost (intent-to-treat population, N = 48)

Table 3 Mean change from baseline on the symptom survey scores (based on a scale of 0–4) after six weeks of therapy with travoprost and tafluprost (intent-to-treat population, N = 48)